Two transport trucks carrying the Sabin strain polio inactivated vaccine (hereinafter referred to as IPV vaccine), from Beijing Bioshen Biological Products Co., Ltd. under the China Biotechnology Co., Ltd. (hereinafter referred to as Zhongsheng) (hereinafter referred to as Beisheng Research) ) Departing from Henan and Shanxi provinces marks the official launch of another domestic IPV vaccine in China. So far, China's IPV vaccine suppliers have entered the "IPV vaccine market" by Sanofi Pasteur (hereinafter referred to as Sanofi), Institute of Medical Biology of the Chinese Academy of Medical Sciences (hereinafter referred to as Kunming Institute) and Beisheng Research. Three Kingdoms period.
　　 Large gap:
Three companies split the IPV vaccine market
Polio (polio), commonly known as poliomyelitis, is a highly infectious disease caused by a virus that occurs in infants and young children and can cause permanent paralysis or even death in a few cases. Since the 1980s, through the promotion of oral trivalent polio attenuated live vaccine (tOPV vaccine, commonly known as "sugar pill"), China has successfully blocked the epidemic.
In 2015, the World Health Organization (WHO) announced the global discontinuation of the tOPV vaccine, switching to a bOPV vaccine containing both serotypes I and III, and requiring countries to introduce and inoculate at least one dose of IPV vaccine. Since May 1, 2016, 155 countries in the world have simultaneously implemented the polio vaccine immunization strategy conversion. China's immunization planning strategy has also been adjusted simultaneously. All children will receive three doses of oral bOPV vaccine after receiving one dose of IPV vaccine. The market gap in IPV vaccines has followed.
According to the "2016 Annual Report on the Issuance of Biological Products", in 2016, China imported 73.037 million IPV vaccines and 408.824 million domestic IPV vaccines, even if 285.517 million people imported IPV vaccines. The total number of IPV vaccines issued by the vaccine is less than 14 million. However, the number of newborns in China in 2016 was 18.46 million, and there were “zero doses†of polio vaccines that needed supplementary immunization. The IPV vaccine market has a large gap.
Due to market encouragement, R&D institutions are accelerating the development of IPV vaccines. It is reported that in addition to Kunming and Beisheng Research's existing R&D products, China BioWuhan Company, Beijing Kexing Bio, Beijing Tiantan Biology, and Beijing Minhai Biology are actively researching and developing IPV vaccines, including Beijing Kexing Bio and Beijing Tiantan Bio. The research of the enterprise is in the clinical trial stage. The IPV vaccine of China Bio Wuhan Co., Ltd. is expected to submit a production registration application in January 2018, with an estimated production capacity of 15 million doses/year.
At this stage, Sanofi, Kunming and Beishengyan IPV vaccine suppliers occupy the entire market of IPV vaccines in China. Due to the huge market gap, expanding production scale is the common choice of these companies. It is reported that the IPV vaccine expansion project under construction in Kunming is expected to be completed in 2018, when the annual production capacity will reach 60 million doses. The annual production capacity of Beisheng Research's IPV vaccine is 40 million to 50 million doses, and will be put on the market in a short period of time. "In the next three months, we expect 10 million doses of IPV vaccine to be launched," said Yang Xiaoming, chairman of Zhongsheng.
　　 go out:
“Beisheng Research†IPV will apply for WHO pre-certification
Compared with the first company to enter the Chinese market, Sanofi and the domestic IPV vaccine startup Kunming, Beisheng Research's IPV vaccine does not occupy the first-mover advantage, but it is also significant, which makes China's IPV vaccine accessibility further improved because there are two locals. The support of enterprise R&D and production has reached the threshold of the National Immunization Program (EPI).
"The domestic IPV vaccine including the Beisheng Research IPV vaccine will greatly enhance the accessibility of this vaccine in China." Yang Xiaoming explained that the availability of vaccine is to enable the vaccinator to obtain a good vaccine at a reasonable price, that is, to Guaranteed price reduction. From the price point of view, the domestic IPV vaccine single price is about 35 yuan, and the difference between imported products and products is nearly 10 times; and in terms of quantity, the number of imported vaccines is limited, and domestic vaccines just make up for the gap.
The biggest significance of the listing of Beisheng Research IPV vaccine is that it must meet the requirements of two or more domestic manufacturers in China's EPI project. In other words, Beisheng Research IPV vaccine is listed, which ensures the demand for polio immunity in China's EPI project. This is related to the public health security of our children," said Zhang Yuntao, assistant to the president of Zhongsheng.
While actively launching IPV vaccines to meet the domestic market supply, Beisheng Research will also look into the international market. Yang Xiaoming revealed that the Beisheng Research IPV vaccine will apply for WHO pre-certification and hope to join the international vaccine supply system. "At present, China is in a state of no polio, but there are polio epidemic in Afghanistan and Pakistan, and China faces the risk of poliovirus input." The relevant person in charge of Zhongsheng explained.
Pre-certification by WHO is the minimum standard for global supply of vaccines. In this respect, Zhongsheng has more mature experience. Yang Xiaoming introduced that in 2013, Zhongjidu Company's live attenuated Japanese encephalitis vaccine became the first Chinese vaccine to receive WHO pre-certification. Currently, the export volume has exceeded 200 million doses, and the mid-life bOPV vaccine was also adopted in April this year. An on-site inspection of the WHO pre-certification and an order for UNICEF (UNICEF) of $8 million.
Nursing pad is a disposable sanitary product made of PE film, non-woven fabric, fluff pulp, polymer and other materials.
Adult nursing pads are mainly used for people who have undergone surgery, those who are paralyzed, and those who cannot take care of themselves. The adult nursing pad is easy to replace, which can ensure that the mattress under the building will not be soiled.
Underpads For Bed,Reusable Bed Underpad,Incontinence Underpads,Washable Underpads For Incontinence
Shandong Kangshun Daily Products Co., Ltd , https://www.centurybenifit.com